APP and Alzheimer disease: A study on the circadian rhythm in APP/PS1 mice showed that the most significant effects of the APPxPS1 transgenes were phase delays of ~2 h in the onset of daytime wakefulness bouts and peak wakefulness, which potentially relevant to phase delays previously reported in AD patients [13].